Fennec Pharmaceuticals GAAP EPS of -$0.11 misses by $0.08, revenue of $9.65M beats by $0.09M

* Fennec Pharmaceuticals press release [https://seekingalpha.com/pr/20200624-fennec-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:FENC [https://seekingalpha.com/symbol/FENC]): Q2 GAAP EPS of -$0.11 misses by $0.08.
* Revenue of $9.65M (+32.9% Y/Y) beats by $0.09M.
* For the second quarter of 2025, the Company recorded net product sales of approximately $9.7 million compared to $7.3 million in the second quarter of 2024. The increase in sales is attributable to the expanded focus and growth in the AYA population, as well as the successful growth and retention of existing accounts within this population.

MORE ON FENNEC PHARMACEUTICALS

* Seeking Alpha’s Quant Rating on Fennec Pharmaceuticals [https://seekingalpha.com/symbol/FENC/ratings/quant-ratings]
* Historical earnings data for Fennec Pharmaceuticals [https://seekingalpha.com/symbol/FENC/earnings]
* Financial information for Fennec Pharmaceuticals [https://seekingalpha.com/symbol/FENC/income-statement]